IceCure Medical Ltd (NASDAQ:ICCM) Short Interest Up 5.1% in June

IceCure Medical Ltd (NASDAQ:ICCM) was the target of a large increase in short interest during the month of June. As of June 15th, there was short interest totalling 164,300 shares, an increase of 5.1% from the May 31st total of 156,400 shares. Based on an average daily volume of 405,600 shares, the short-interest ratio is presently 0.4 days. Currently, 0.8% of the company’s stock are short sold.

IceCure Medical Stock Performance

ICCM stock opened at $0.74 on Thursday. The company has a market cap of $33.73 million, a P/E ratio of -2.24 and a beta of 0.57. IceCure Medical has a 1 year low of $0.52 and a 1 year high of $1.57. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.39 and a quick ratio of 2.88. The stock’s fifty day moving average price is $0.97 and its 200-day moving average price is $1.15.

IceCure Medical (NASDAQ:ICCM) last released its earnings results on Tuesday, May 28th. The company reported ($0.08) earnings per share for the quarter, meeting the consensus estimate of ($0.08). The company had revenue of $0.74 million for the quarter, compared to the consensus estimate of $0.80 million. IceCure Medical had a negative return on equity of 101.66% and a negative net margin of 444.30%. During the same period in the previous year, the business earned ($0.08) earnings per share. On average, equities analysts forecast that IceCure Medical will post -0.28 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have commented on ICCM. HC Wainwright reiterated a “buy” rating and set a $3.00 target price on shares of IceCure Medical in a research note on Tuesday. Alliance Global Partners increased their target price on IceCure Medical from $1.90 to $2.90 and gave the company a “buy” rating in a research note on Wednesday, March 20th.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.